ecancer

Nominations are OPEN for the McVie–Veronesi Award 2026 🌍 Know someone making a real impact in cancer care in #LMICs? ✨ Nominate them today or nominate yourself! 🗓️ Deadline: May 8, 2026 📩 Submit applications to: maria@ecancer.org 🏆 Presented at the #ASCO Annual Meeting (virtual option available) #GlobalOncology #CancerControl #EducationSavesLives

⭐ Patient perspective on side effects what really matters? @OncoAlert @APCCC_Lugano #APCCC26 @Silke_Gillessen @AOmlin Presented by Brian Jones 🔹 A powerful reminder: patients experience toxicity differently than we measure it 🔹 Key insights: • Peer support groups → reduce isolation and improve coping • Open discussion of side effects → better communication with care teams • Simple connection (calls/messages) → meaningful patient support • Education beyond cancer → mental health, diet, exercise, survivorship 🔹 Big message: Side effects are not just clinical events → they are lived experiences that need to be shared and understood 🔹 Take-home: Better outcomes require more than treatments → they require listening, connection and support 👏 A truly human and impactful talk @ASCO @myESMO @urotoday @ecancer @MedicalwatchHQ @urologysummit #ProstateCancer #UroOncology #Oncology

Dr Toni Choueiri from the Dana-Farber Cancer Institute shares the results of phase-III LITESPARK-022 study. Combination therapy with pembrolizumab + belzutifan as adjuvant therapy significantly improved disease-free survival compared with pembrolizumab alone in patients with clear cell renal cell carcinoma. Full interview here 👉 #ASCOGU26" target="_blank" rel="nofollow noopener">ecancer.org/en/video/12824…

ctDNA predicts early treatment response in HPV-associated anal cancer - ecancer @ecancer ecancer.org/en/video/12912…

ARANOTE post hoc analyses indicate that darolutamide improved PFS in patients with metastatic hormone-sensitive prostate cancer regardless of comorbidities and concomitant medications. Prof Fred Saad discusses how these findings support darolutamide as a reliable and broadly applicable treatment option 👉 #ASCOGU26" target="_blank" rel="nofollow noopener">ecancer.org/en/video/12823…

First-in-human results from the PAnTHa trial show 225Ac-PSMA-trillium is well tolerated and highly active in metastatic castration-resistant prostate cancer (mCRPC). Prof Fred Saad from @chumontreal speaks to ecancer here 👉 #ASCOGU26" target="_blank" rel="nofollow noopener">ecancer.org/en/video/12821…

RAMPART trial indicates that while combination therapy with durvalumab plus tremelimumab improved disease-free survival, QoL was temporarily affected. These findings can inform patient discussions about balancing treatment benefits with tolerability. Watch the full interview with Dr Sophie Merrick from @ucl here 👇 #ASCOGU26" target="_blank" rel="nofollow noopener">ecancer.org/en/video/12820…

Induction ipilimumab + nivolumab followed by chemoradiotherapy achieves high bladder preservation and event-free survival in patients with muscle-invasive bladder cancer. Dr Jan-Jaap Mellema from The Netherlands Cancer Institute @NKI_nl discusses the trial here 👉 #ASCOGU26" target="_blank" rel="nofollow noopener">ecancer.org/en/video/12819… #MIBC

Dr Michael Morris shares results of the PSMAddition trial: Findings suggest that a combination of 177Lu-PSMA-617 with androgen deprivation therapy plus androgen receptor pathway inhibitor therapy significantly improved PFS in patients with mHSPC. Full interview here 👉 #ASCOGU26" target="_blank" rel="nofollow noopener">ecancer.org/en/video/12818… @MSKCancerCenter @morr316

Patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) prefer androgen receptor pathway inhibitor-based therapy over androgen deprivation therapy alone. Dr Neal Shore speaks about patient’s preferences for treatment of nmHSPC in full interview here 👉 ecancer.org/en/video/12817… @CURCMB #ASCOGU26

Dr Neal Shore shares findings of EMBARK trial evaluating combination therapy with enzalutamide plus leuprolide. Results highlight the long-term benefit of combination therapy over monotherapy approaches. Interview with Dr Shore here 👇 ecancer.org/en/video/12816… @CURCMB #ASCOGU26

Nominations are OPEN for the McVie–Veronesi Award 2026 🌍 Know someone making a real impact in cancer care in #LMICs? ➡️Nominate them today or nominate yourself! ➡️Submit applications to: maria@ecancer.org ⭐️ Presented at the #ASCO Annual Meeting (virtual option available) #CancerControl #EducationSavesLives

Trial suggests that cabozantinib treatment provides a non-chemotherapeutic approach with disease control and a manageable safety profile in pretreated relapsed refractory germ-cell tumours (GCT). Full interview available here 👉 ecancer.org/en/video/12815… #ASCOGU26

Doctor Kalantri highlights the importance of transparency and consistent adherence to prespecified patient-reported outcome measures in genitourinary oncology studies. Watch the interview 👇 ecancer.org/en/video/12814… #ASCOGU26 @KalantriShreyas

Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC - ecancer 🧵 6-year follow-up in advanced NSCLC – EMPOWER-Lung 1 trial 1/Long-term data matters. It tells us not just if a drug works—but how durable that benefit truly is. The 6-year follow-up of the EMPOWER-Lung 1 trial brings important clarity. 2/First-line cemiplimab monotherapy in advanced NSCLC with high PD-L1 expression: ✔️ Improved Overall Survival ✔️ Better Progression-Free Survival ✔️ Higher Response Rates Compared to standard chemotherapy. 3/What stands out most? 👉 Patients with very high PD-L1 expression derived the greatest benefit 👉 Those completing the full course had remarkable long-term outcomes This reinforces the biology-driven approach in lung cancer 4/ Safety profile: 🔹 Grade ≥3 adverse events • Cemiplimab: 45.8% • Chemotherapy: 51.6% ➡️ Lower toxicity burden compared to chemo, with sustained efficacy. 5/Why is this important? Because in advanced lung cancer, we are no longer just aiming for response… We are aiming for durable survival and meaningful life extension. 6/This study strengthens the role of immunotherapy as frontline standard in selected patients. Right patient. Right biomarker. Right treatment. That’s precision oncology in action. 7/Take-home message: Cemiplimab offers a compelling long-term benefit-risk profile in high PD-L1 advanced NSCLC. And reminds us— Testing PD-L1 is not optional. It is essential. 8/As oncologists, our responsibility is clear: 👉 Identify eligible patients early 👉 Use biomarkers wisely 👉 Maximize survival—not just short-term response #LungCancer #Immunotherapy #Oncology #PDL1 #PrecisionMedicine #CancerCare #MedTwitter @OncoDailyIO @oncodaily @OncoAlert @lcrf_org @ecancer Here is the Link ! ecancer.org/en/video/12903…

Dr @lalaniMD shares insights from CYTOSHRINK – a trial that evaluated stereotactic body radiation therapy (SBRT) combined with ipilimumab and nivolumab vs ipilimumab or nivolumab alone. Full detail from Dr. Lalani here 👉 ecancer.org/en/video/12813… #ASCOGU26

Bringing Cancer Knowledge to Every Corner: How eCancer Delivers Free Education Worldwide In this episode of Global Health Unpacked, Dr. Gvantsa Khizanishvili sits down with Danny Burke, Chief Executive Officer of @ecancer, to explore how innovative education models are reshaping global oncology. This weekly OncoDaily series highlights the latest global health trends by engaging with leaders driving change in cancer care and beyond. Danny Burke shares the story behind eCancer’s mission to make high-quality oncology education freely accessible worldwide, particularly in low- and middle-income countries. The discussion also highlights how local collaboration is key to impactful education, ensuring that content is not only cutting-edge but also relevant to real-world clinical environments. From developing region-specific curricula to supporting research from underrepresented communities, eCancer is building a sustainable model that connects education, research, and patient care. Exploring how AI can break language barriers and create a future where knowledge is not limited by language, and resources are accessible to anyone, anywhere, in their own language.

KEYNOTE-905 trial shows that enfortumab vedotin plus pembrolizumab significantly improved pathological complete response, pathological down-staging, and disease-free survival in MIBC. Full interview with Professor Steffen Rausch from @uni_tue here 👉 ecancer.org/en/video/12812… #ASCOGU26

🌟Oligorecurrent HSPC: are we overinterpreting early signals? @JCO_ASCO @OncoAlert @APCCC_Lugano The ongoing discussion around the LUNAR trial reminds us of something essential: 👉 not all “oligometastatic” disease behaves the same 🔹 1. Imaging is redefining disease • PSMA-PET is identifying smaller-volume recurrence 👉 But are we changing biology… or just detecting it earlier? 🔹 2. MDT enthusiasm vs evidence • Metastasis-directed therapy is appealing • But survival impact remains uncertain 👉 Are we treating lesions… or the disease? 🔹 3. The systemic component remains key • Even in low-volume recurrence • Risk of micrometastatic disease persists 👉 Local control ≠ disease control 💡 My take: Oligorecurrence sits in a grey zone between localized and systemic disease 👉 The challenge is not whether to treat 👉 but how much and for how long 🔗 bit.ly/4m8n921 @ecancer @urotoday @UrologyTimes @MedicalwatchHQ @urologysummit #ProstateCancer #pcsm #Oligometastatic #PrecisionOncology #OncoTwitter

Phase III CHHiP trial externally validated a digital pathology-based multimodal artificial intelligence (MMAI)-derived prognostic biomarker. @DrAnnaWilkins says that incorporating MMAI into existing risk models significantly improved predictive accuracy and model fit. Full interview here 👇 ecancer.org/en/video/12811… #ASCOGU26